CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: a Prospective, Randomized, Double-blind, Multi-center Clinical Trial

Status: Active_not_recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this study is to evaluate the efficacy and safety of chemotherapeutic pancreatic cyst ablation using ethanol lavage followed by the infusion of a dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) compared with alcohol-free saline lavage followed by infusion of the same dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) for the ablation of pancreatic cystic neoplasms using endoscopic ultrasound guided fine needle infusion (EUS-FNI) for agent delivery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult subjects over the age of 18.

• Patients with a previously-detected pancreatic cyst(s) 2-5 cm in diameter which is consistent with a mucinous type cyst as per ASGE guidelines, including indeterminate type cysts.

• Able to give written informed consent.

• Capable of safely undergoing endoscopy with deep sedation or general anesthesia.

Locations
United States
Indiana
Indiana University Health University Hospital
Indianapolis
Pennsylvania
Penn State Health Milton S. Hershey Medical Center
Hershey
Time Frame
Start Date: 2019-04-12
Completion Date: 2025-02-01
Participants
Target number of participants: 75
Treatments
Active_comparator: Control Group
Cyst will be lavaged for 3 to 5 minutes with \>/=99% ethanol. Following lavage with \>/=99% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
Experimental: Study group
Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
Sponsors
Collaborators: National Cancer Institute (NCI)
Leads: Milton S. Hershey Medical Center

This content was sourced from clinicaltrials.gov